JCR Pharmaceuticals Co., Ltd.(JP:4552)
¥499.00+6.00 (+1.22%)
JP:4552
JCR Pharmaceuticals Co., Ltd. earnings date
¥499.00
At close:+6.00 (+1.22%)
Want to see JP:4552 full AI Analyst Report?
JCR Pharmaceuticals Co., Ltd. (4552) Q2 2023 Earnings Report
1 Followers
JP:4552 Q2 2023 EPS Results
- Actual EPS
- JPY 29.19
- Consensus EPS
- JPY 12.95
- Beat/Miss
- Beat by +JPY 16.24
- One Year Ago EPS
- -JPY 3.29
JP:4552 Q2 2023 Revenue Results
- Actual Revenue
- JPY 13.46B
- Expected Revenue
- JPY 10.15B
- Beat/Miss
- Beat by +JPY 3.31B
- YoY Revenue Growth
- +125.34%
Earnings Announcement Details
- Quarter
- Q2 2023
- Date
- 10/25/2023
- Time
- TBA
- Conference Call
- Wednesday, October 25, 2023
JP:4552 Upcoming Earnings
JCR Pharmaceuticals Co., Ltd.'s next earnings date is estimated for January 28, 2027, based on past reporting schedules.
Q2 2023 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2023 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2023 Earnings Call Summary
No earnings call summary is available for this earnings event.
JP:4552 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Jan 28, 2027 | 2026 (Q3) | -13.83- | 0.27 | ― | ― |
| Oct 29, 2026 | 2026 (Q2) | ―-16.03 | 18.51 | -186.60% (-34.54) | |
| Jul 30, 2026 | 2026 (Q1) | -11.27-15.64 | -4.48 | -249.11% (-11.16) | |
| May 13, 2026 | 2025 (Q4) | -6.633.57 | -33.8 | 110.56% (+37.37) | |
| Jan 28, 2026 | 2025 (Q3) | -1.070.27 | 0.9 | -70.00% (-0.63) | |
| Oct 30, 2025 | 2025 (Q2) | 20.3918.51 | -7.14 | 359.24% (+25.65) | |
| Jul 30, 2025 | 2025 (Q1) | 4.36-4.48 | 1.61 | -378.26% (-6.09) | |
| May 13, 2025 | 2024 (Q4) | -53.70-33.80 | 2.78 | -1315.83% (-36.58) | |
| Jan 31, 2025 | 2024 (Q3) | 11.180.90 | -0.75 | 220.00% (+1.65) | |
| Oct 30, 2024 | 2024 (Q2) | 13.72-7.14 | 29.19 | -124.46% (-36.33) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

